Lymphoma
Lymphomas are a diverse group of hematologic malignancies that typically develops in lymph nodes and can originate from B cells, T cells, and natural killer cells. They are broadly divided into 2 categories, Hodgkin lymphoma and non-Hodgkin lymphoma.
Aggressive B-Cell Lymphoma
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
The MZL cohort of a phase 2 study saw the most success from the atezolizumab plus obinutuzumab and venetoclax regimen.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Glofitamab combos show high, durable responses in high-risk LBCL, per phase II COALITION trial in younger patients.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
Hodgkin Lymphoma
Immunotherapy is transforming lymphoma treatment, reducing chemo reliance, and improving long-term outcomes.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
The model estimates patients' 2-year progression-free survival using patient information routinely recorded in the clinic.
Indolent B-Cell Lymphoma
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Steady access to Medicaid insurance helps ensure early recognition of symptoms, said senior author Xu Ji, PhD.
Mantle Cell Lymphoma
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
Guest contributor Charles Gaulin, MBBS, outlines important updates on the first-line treatment of TP53-mutated MCL.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Sonrotoclax plus zanubrutinib shows promising efficacy and safety in relapsed/refractory MCL, per EHA 2025 data.
T-Cell Lymphoma
Cemiplimab + isatuximab combo shows 51% CR and promising safety in R/R ENKTL, exceeding study endpoint.
Novel PI3Kδ + HDACi combo shows promise for relapsed/refractory CTCL, with favorable outcomes and manageable safety.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Paola Ghione, MD, discusses these findings and how breast implant-associated anaplastic large cell lymphoma is managed.
11 of 17 patients who achieved a complete or partial response were able to bridge to HSCT.
Josie Ford, of Mass General Hospital, shared real-world efficacy and safety data on duvelisib and romidepsin in PTCL.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.